D&A at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s D&A?
- Oruka Therapeutics, Inc. (ORKA) reported D&A of $43K in Q1 2026.
- How has Oruka Therapeutics, Inc.'s D&A changed year-over-year?
- Oruka Therapeutics, Inc.'s D&A increased by 168.8% year-over-year, from $16K to $43K.
- What is the long-term trend for Oruka Therapeutics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Oruka Therapeutics, Inc.'s D&A has grown at a 50.9% compound annual growth rate (CAGR), from $16K to $83K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.